NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

FYI

https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/united-kingdom/amp

The NHS ring-fences funding for certain classes of medicine that receive a particular type of recommendation from NICE.

The Cancer Drugs Fund (“CDF”) is in place to enable faster access to promising new cancer treatments. Following its relaunch in 2016, the CDF aims for all new systemic cancer drugs to receive a fast-tracked NICE appraisal. So far, 102 new oncology drugs treating 242 different indications have been through CDF review. NICE will recommend a product to receive funding from the CDF, at a negotiated price, if it has the potential to satisfy the criteria for routine commissioning but there is clinical uncertainty that needs further investigation (i.e., through data collection in the NHS or clinical studies). The drug will remain available within the CDF while more evidence becomes available, at which point NICE will subject it to one of its standard technology appraisal processes. The CDF has provided a route to NHS funding for a number of highly innovative, high-cost oncology technologies, including CAR-T and certain immuno-oncology therapies. The NHS has guaranteed £340 million per year for the CDF.
Introduced in 2022, the Innovative Medicines Fund (“IMF”) is an analogue to the CDF for non-oncology medicines that show significant clinical promise but for which the evidence base may be immature or uncertain. The primary function of the IMF is to provide managed, interim access to a promising medicine to patients while further evidence is generated to support a full NICE assessment. As with the CDF, the NHS has guaranteed £340 million per year for the IMF.